Management of Decompensated Liver Cirrhosis

Immediate Priority: Treat the Underlying Cause

The American Association for the Study of Liver Diseases recommends immediate initiation of etiological treatment, as this is directly associated with decreased risk of further decompensation and increased survival 1

The European Association for the Study of the Liver suggests that for alcoholic cirrhosis, complete and permanent cessation of alcohol consumption is mandatory, as this can lead to "re-compensation" and excellent long-term outcomes in some patients, though progression may continue in others despite abstinence 2, 1
For hepatitis B-related decompensated cirrhosis, the American Association for the Study of Liver Diseases recommends initiating antiviral therapy immediately regardless of HBV DNA level, and using entecavir or tenofovir as first-line agents due to their potent antiviral efficacy and high genetic barrier to resistance 3

The American College of Gastroenterology recommends that for ascites management, first-line treatment consists of sodium restriction plus spironolactone with or without furosemide 1, 3
For variceal bleeding, the American Association for the Study of Liver Diseases suggests initiating vasoactive drugs immediately upon suspicion of variceal bleeding, even before endoscopic confirmation, and using antibiotic prophylaxis with ceftriaxone or norfloxacin 1, 3

The European Association for the Study of the Liver recommends using non-selective beta-blockers, such as propranolol, in responders to decrease risk of ascites, hepatorenal syndrome, SBP, and hepatic encephalopathy beyond variceal bleeding prevention 1, 5
The American Association for the Study of Liver Diseases suggests that enoxaparin may delay hepatic decompensation and improve survival in patients with Child-Pugh scores 7-10 by preventing portal vein thrombosis and reducing intestinal barrier damage 1, 5

The European Society for Clinical Nutrition and Metabolism recommends performing rapid nutritional screening in all patients, assuming high risk for malnutrition if BMI <18.5 kg/m² or Child-Pugh C, and assessing for sarcopenia using CT scan, anthropometry, DEXA, or BIA 3

The American Diabetes Association recommends that insulin therapy is the only evidence-based option for treating type 2 diabetes in decompensated cirrhosis, and that HbA1c should not be used for diagnosis or assessing glycemic control 4

The American Association for the Study of Liver Diseases recommends that early referral for liver transplantation evaluation is essential for appropriate candidates, as decompensation significantly worsens prognosis, and that mean pulmonary arterial pressure ≥45 mmHg is an absolute contraindication to liver transplantation 1, 5

The American College of Gastroenterology suggests using telemedicine and remote monitoring technologies to enable early detection of complications and reduce hospital readmissions, and that heart rate variability monitoring may identify patients at risk of decompensation 3, 5